Titan Pharmaceuticals, Inc.

281 articles about Titan Pharmaceuticals, Inc.

• Titan Pharmaceuticals Reports Positive Initial Results Of Probuphine® Relaunch

  1/31/2019

  - Double-Digit Increase in Probuphine Shipments -

• Titan Pharmaceuticals Announces Reverse Stock Split on January 24, 2019

  1/24/2019

  Titan Pharmaceuticals, Inc. announced today that it has filed an amendment to its certificate of incorporation that will effect a 1-for-6 reverse stock split of the company's issued and outstanding shares of common stock, warrants and options, which was approved by the company's stockholders at a special meeting held on January 23, 2019.

• Titan Pharmaceuticals Reports Third Quarter 2018 Financial Results

  11/14/2018

  Titan Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2018, and provided an update on its business.

• Titan Pharmaceuticals Schedules Conference Call To Review Third Quarter 2018 Financial Results

  11/8/2018

  Management Team to Host Conference Call Nov. 14 at 4:15 p.m. EST / 1:15 p.m. PST

• Refuge Biotechnologies Appoints Scott Smith to Board of Directors

  10/15/2018

  Former President and COO of Celgene to Help Guide Pipeline and Corporate Development Activities.

• Titan Strengthens Executive Leadership Team With Appointment Of Chief Commercial Officer

  10/2/2018

  Mr. Hallberg will be responsible for leading all of the company's commercial activities.

• Titan Pharmaceuticals Prices $9,500,000 Public Offering

  9/21/2018

  Titan Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering with expected total gross proceeds of $9,500,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company.

• Titan And The Nevada Center For Behavioral Health Collaborate To Evaluate Probuphine® Treament Of OUD Patients Within The State Of Nevada Criminal Justice System

  9/4/2018

  Titan Pharmaceuticals, Inc. today announced the initiation of a pilot program in collaboration with the Nevada Center for Behavioral Health (NCBH) to evaluate a medication-assisted treatment (MAT) program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients within the State of Nevada criminal justice system.

• Titan Pharmaceuticals Reports Second Quarter 2018 Financial Results

  8/14/2018

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, today reported financial results for the second quarter ended June 30, 2018, and provided an update on its business.

• Titan Announces Amendment To Agreement With Molteni

  8/3/2018

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has entered into an amendment (the "Amendment") of the previously announced definitive asset purchase, supply and support agreement (the "Purchase Agreement") with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. through which Molteni acquired the European intellectual property related to Probuphine®.

• 

  Titan Pharma Receives Go-Ahead with Parkinson’s Trial, But Chooses to Hold Off

  7/3/2018

  An independent Data Safety Monitoring Board (DSMB) recommended that Titan Pharmaceuticals’ Phase I/II trial of its ropinirole implant for Parkinson’s disease continue with a second cohort of patients. However, the company has decided to temporarily halt the study and focus on another asset.

• Titan Pharmaceuticals Provides Update On Parkinson's Disease Clinical Development Program

  7/2/2018

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, announced today that the independent Data Safety Monitoring Board ("DSMB") for the company's Phase 1/2 trial...

• Titan Pharmaceuticals And Braeburn Announce Mutual Termination Of License Agreement For Probuphine® For Opioid Dependence

  5/30/2018

  Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) and Braeburn announce that they have agreed to terminate the December 2012 license agreement, which granted Braeburn exclusive rights to commercialize Probuphine in the United States and Canada.

• Accomplished Global Pharmaceutical Executive, Federico Seghi Recli, Appointed To Titan's Board

  5/14/2018

  Titan develops proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology.

• Titan Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results

  4/2/2018

  Titan Management Team to Host Conference Call April 2 at 4:15 p.m. EDT / 1:15 p.m. PDT

• Titan Executes Agreement For Acquisition By Molteni Of Probuphine® In Europe And Other Select Territories

  3/21/2018

  Titan Pharmaceuticals, Inc. announced that it has entered into a definitive asset purchase, supply and support agreement with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A.

• Titan Announces Amendment to Horizon Loan Agreement

  2/5/2018

  Pursuant to this amendment, Titan will prepay $3M of the outstanding $7M principle amount, with an additional $1M prepayment due on the earlier of.

• Titan in Discussions With Braeburn Regarding U.S. Probuphine Commercialization

  1/22/2018

  Braeburn's receipt of a CRL from the FDA regarding the NDA for its injectable buprenorphine product is likely to negatively impact Braeburn's Probuphine marketing activities as it focuses on addressing the CRL.

• EMA Accepts Titan Pharma's MAA for Probuphine

  11/27/2017

  The acceptance marks the beginning of the EMA's regulatory review process for Probuphine for substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment.

• Titan Pharmaceuticals Reports Third Quarter 2017 Financial Results

  11/9/2017

  Titan reported approximately $40,000 in license revenue from royalties earned on net sales of Probuphine by Braeburn, compared with approximately $26,000 in the same period a year ago.